Find Small Cell Lung Cancer (SCLC) Clinical Trials Near You
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Participants have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
• Male or female subjects ≥ 18 years old. For Part 1, age ≥18 years and ≤75 years;
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
• Minimum life expectancy of ≥ 12 weeks;
• Adequate organ function confirmed at screening period;
• Histologically or cytologically confirmed unresectable,metastatic or Extensive-Stage small cell lung cancer (SCLC).
Locations
Other Locations
Australia
Austin Hospital
RECRUITING
Heidelberg
Westmead Hospital
RECRUITING
Westmead
Wollongong Hospital
NOT_YET_RECRUITING
Wollongong
China
Hunan Cancer Hospital
RECRUITING
Changsha
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITING
Fuzhou
Zhejiang Cancer Hospital
RECRUITING
Hangzhou
The First Affiliated Hospital of Anhui Medical University
NOT_YET_RECRUITING
Hefei
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
NOT_YET_RECRUITING
Jinan
The First Affiliated Hospital of Nanchang University